Sickle Cell Disease Treatment in India and UAE | Complete Patient Guide

• **Eligible for Allogeneic BMT (Curative Intent):**

• Children and young adults (ideally under 16 years; adult BMT up to age 40–45 at experienced centers) with severe SCD (HbSS or HbSβ⁰-thalassemia genotype)

• History of ≥2 acute chest syndrome episodes, ≥1 clinical stroke or silent cerebral infarct on MRI, recurrent severe VOC (≥3 hospitalizations/year despite hydroxyurea), chronic transfusion dependency, or progressive sickle nephropathy

• Availability of an HLA-matched sibling donor (10/10 match preferred; haploidentical protocols expanding eligibility)

• Lansky/Karnofsky performance score ≥70; acceptable cardiac function (ECHO: LVEF ≥50%, no pulmonary hypertension with TR jet velocity >2.5 m/s on Doppler)

• Adequate renal function (GFR >60 mL/min/1.73m²) and hepatic function (no cirrhosis; MRI-based liver iron concentration assessed)

• **Eligible for Hydroxyurea / Advanced Medical Management:**

• Any SCD patient (HbSS, HbSC, HbSβ-thalassemia) with recurrent VOC, ACS, symptomatic anemia, or priapism

• No BMT donor available or patient/family declining transplant

• Patients with mild-to-moderate disease seeking to defer or avoid transplant

• **Required Pre-Treatment Diagnostics:**

• Complete blood count with reticulocyte count, peripheral blood smear, hemoglobin electrophoresis (HPLC)

• HbF quantification (baseline and on-treatment monitoring)

• HLA typing (patient and all potential donors: siblings, parents)

• Brain MRI/MRA (silent infarct screening), transcranial Doppler ultrasound (TCD) for stroke risk stratification

• Echocardiography (pulmonary hypertension screening via TR jet velocity; LV function assessment)

• Serum ferritin and MRI T2* (liver and cardiac iron quantification)

• Pulmonary function tests (FEV1, FVC, DLCO)

• Ophthalmology review (proliferative sickle retinopathy)

• Renal function panel (serum creatinine, urine albumin-to-creatinine ratio, GFR estimation)

• Infectious serology (HIV, Hepatitis B/C, CMV, EBV, Toxoplasma — mandatory pre-BMT)

• Bone density scan (DEXA) if chronic steroid use or avascular necrosis suspected

• **Contraindications to BMT:**

• Severe, irreversible end-organ damage (advanced sickle nephropathy with GFR <30, severe pulmonary hypertension, decompensated liver cirrhosis)

• Active uncontrolled infection at time of conditioning

• No compatible donor (relative contraindication; haploidentical protocols mitigating this barrier)

• Patient/guardian refusal of immunosuppression or transplant protocol

• Prior severe allergic reaction to conditioning agents (busulfan, cyclophosphamide, fludarabine)

**1. Hydroxyurea (Hydroxycarbamide) Therapy — Disease Modification**

Hydroxyurea remains the cornerstone pharmacological intervention for SCD. It acts by inducing fetal hemoglobin (HbF) synthesis through S-phase inhibition of ribonucleotide reductase, elevating HbF to 15–25% of total hemoglobin in responders, which sterically inhibits HbS polymer chain propagation. Standard dosing begins at 15 mg/kg/day orally, titrated over 6–12 weeks to maximum tolerated dose (MTD) of 25–35 mg/kg/day guided by complete blood count monitoring (target: ANC 2,000–4,000/µL, avoiding neutropenia). Response is assessed at 3–6 months. The BABY HUG trial confirmed benefit in infants as young as 9 months. Leading Indian centers and UAE programs now offer pharmacogenomic profiling (BCL11A variant analysis) to predict HbF response prior to initiation.

**2. Novel Pharmacological Agents**

• **Voxelotor (Oxbryta):** A first-in-class HbS polymerization inhibitor that binds covalently to the N-terminal valine of the α-chain of hemoglobin, stabilizing the oxygenated conformation and preventing sickling. Approved for patients ≥4 years; raises Hb by 1–2 g/dL and reduces hemolysis markers. Available at select centers in India (Apollo, Fortis, AIIMS) and UAE (Cleveland Clinic Abu Dhabi, King's College Hospital Dubai).

• **Crizanlizumab (Adakveo):** Humanized anti-P-selectin monoclonal antibody administered IV every 4 weeks; reduces VOC frequency by ~45% vs. placebo (SUSTAIN trial). Particularly beneficial in patients with high adhesion-mediated crises.

• **L-Glutamine (Endari):** Oral amino acid supplement reducing NAD redox imbalance in sickle erythrocytes; reduces ACS and hospitalization frequency.

• **Chronic Transfusion Therapy:** Used for primary/secondary stroke prevention and severe ACS. Automated red cell exchange (erythrocytapheresis) is preferred over simple transfusion to maintain HbS fraction <30% while limiting iron accumulation. Chelation therapy (deferasirox oral or deferoxamine SC/IV) is co-administered to manage transfusional iron overload.

**3. Allogeneic Bone Marrow / Hematopoietic Stem Cell Transplantation (BMT/HSCT) — Curative**

BMT offers the only proven cure for SCD. The standard myeloablative conditioning regimen for matched sibling donor (MSD) transplant is the **Bu/Cy protocol**: Busulfan (IV, pharmacokinetically dosed targeting AUC 900–1,200 µM·min to minimize neurotoxicity) combined with Cyclophosphamide and Anti-Thymocyte Globulin (ATG, Graft-vs.-Host Disease prophylaxis). Reduced-intensity conditioning (RIC) using Fludarabine-based regimens is preferred for older patients or those with comorbidities, trading a small increase in graft failure risk for reduced treatment-related mortality (TRM).

• **Stem Cell Sources:** Bone marrow harvest (preferred in pediatric MSD transplant — lower chronic GvHD rate vs. PBSC), peripheral blood stem cells (G-CSF mobilized, used in adult/RIC protocols), and umbilical cord blood (UCB, used when no MSD available but associated with higher graft failure risk).

• **HLA Matching:** 10/10 HLA-matched sibling is the gold standard. Matched unrelated donor (MUD, 10/10) outcomes are improving with better supportive care. Haploidentical (half-matched parent/sibling) transplant using post-transplant cyclophosphamide (PTCy) GvHD prophylaxis is a rapidly growing option at expert centers when no matched donor exists.

• **GvHD Prophylaxis:** Calcineurin inhibitor (tacrolimus or cyclosporine) + short-course methotrexate (MSD/MUD) or PTCy + tacrolimus + mycophenolate mofetil (haplo protocols).

• **Engraftment Monitoring:** Weekly chimerism analysis (STR-PCR) targets ≥95% donor chimerism by Day +30–60. Mixed chimerism (>20% recipient) is managed with donor lymphocyte infusion (DLI) or immunosuppression reduction.

**4. Emerging/Gene Therapy Approaches (Available at Trial Level)**

• **Betibeglogene Spartivec (Zynteglo):** Lentiviral vector delivering a functional βA-T87Q-globin gene into autologous HSCs; now FDA/EMA approved and entering programs at select centers. Eliminates donor dependency and GvHD risk.

• **CRISPR-Cas9 Exagamglogene Autotemcel (Casgevy):** Reactivates fetal hemoglobin via BCL11A enhancer editing; FDA approved (Dec 2023). Clinical access in India and UAE is in early rollout through international trial affiliations.

**5. Acute Crisis Management Protocol**

• Vaso-occlusive crisis: IV crystalloid hydration (1.5× maintenance), IV/SC opioid analgesia (morphine or hydromorphone via PCA), NSAID adjuncts (ketorolac), incentive spirometry q1–2h, oxygen supplementation targeting SpO2 >95%

• Acute Chest Syndrome (ACS): Supplemental oxygen, broad-spectrum antibiotics (macrolide + cephalosporin), bronchodilators, simple or exchange transfusion to reduce HbS% to <30%

• Stroke: Emergency exchange transfusion targeting HbS <30%, followed by chronic transfusion program or expedited BMT evaluation

• Priapism (>4 hours): Aspiration and irrigation of corpora cavernosa, IV hydration, exchange transfusion; penile sympathomimetic injection (etilefrine/phenylephrine)

**Phase 1 — Remote Pre-Assessment (Weeks 1–3, from home country)**

• GAF Healthcare coordinates upload of medical records: CBC with differential, hemoglobin electrophoresis/HPLC report, HbF level, serum ferritin, MRI brain, ECHO report, and any prior treatment history to the designated Indian or UAE hematology team

• Virtual MDT consultation (hematologist + transplant physician) to determine treatment pathway: hydroxyurea optimization, BMT workup, or crisis management

• For BMT candidates: HLA typing specimens (buccal swab or blood) arranged via GAF partner laboratory in home country for donor-patient matching

• Visa application initiated: India e-Medical Visa (typically approved in 3–5 business days); UAE tourist/medical visa assistance

**Phase 2 — Arrival & Comprehensive Pre-Treatment Workup (Days 1–7 in-country)**

• Airport pickup by GAF-assigned coordinator; accommodation arranged near treating hospital

• Full admission workup: repeat CBC, reticulocyte count, LFTs, RFTs, viral serology (CMV/EBV/HIV/HBV/HCV), coagulation profile, 24-hour urine protein, chest X-ray, ECHO, PFTs, brain MRI/MRA, ophthalmology review, dental clearance (mandatory pre-BMT to eliminate infection foci)

• Infectious disease clearance and antimicrobial prophylaxis initiated (penicillin V prophylaxis confirmed; co-trimoxazole, fluconazole, acyclovir prophylaxis added pre-BMT)

• Bone marrow donor workup (for matched sibling): donor health assessment, bone marrow harvest scheduling

• Nutritional assessment; physiotherapy baseline assessment; psychological support consultation

**Phase 3a — Hydroxyurea Initiation / Crisis Management (Days 7–14)**

• Hydroxyurea commenced at 15 mg/kg/day; baseline HbF, CBC documented

• Acute crisis treatment if required: IV fluids, PCA opioid protocol, ACS monitoring with daily chest auscultation and SpO2

• Exchange transfusion arranged if HbS% targets require reduction

• Discharge planning: hydroxyurea prescription, CBC monitoring schedule, emergency protocol card provided

**Phase 3b — BMT Conditioning & Transplantation (Days 7–21, in-hospital)**

• Central venous catheter (CVC/Hickman line) placement under image guidance

• Myeloablative conditioning: IV Busulfan (Days -7 to -4, PK-dosed); Cyclophosphamide (Days -3 to -2); ATG (Days -3 to -1)

• Day 0: Stem cell infusion (bone marrow harvest from sibling donor or thawed cord blood unit); typically a 30–60 minute IV infusion monitored in transplant unit

• Engraftment phase (Days +1 to +30): daily CBC, electrolytes, LFTs; G-CSF support; mucositis management (magic mouthwash, IV analgesia, TPN if oral intake compromised); infection surveillance (daily temperature, CXR twice weekly, CMV/EBV PCR weekly)

• Neutrophil engraftment milestone: ANC >500/µL on 3 consecutive days (typically Day +14 to +21 for bone marrow; Day +10 to +18 for PBSC)

• Platelet engraftment: >20,000/µL unsupported (typically Day +20 to +30)

**Phase 4 — Early Post-Transplant Monitoring (Days +30 to +100, outpatient near hospital)**

• Outpatient clinic visits 2–3× per week: CBC, chimerism analysis (Day +30, +60, +100), tacrolimus/cyclosporine levels, CMV/EBV PCR

• GvHD surveillance: skin, gut, liver assessment at each visit; early acute GvHD (Grades I–II) managed with topical steroids and systemic methylprednisolone

• Immunosuppression taper begins at Day +60–90 if full donor chimerism confirmed and no active GvHD

• Dietary restrictions (neutropenic diet lifted after ANC consistently >1,000/µL)

• Milestone: Fit-to-fly assessment at Day +90–180 based on immune reconstitution, chimerism stability, and absence of active GvHD or infection

**Phase 5 — Long-Term Follow-Up (Month 3–24, coordinated with home-country physician via GAF telemedicine)**

• Monthly CBC, chimerism, immunoglobulin levels; vaccination schedule restart at Month +6 (live vaccines at Month +24 post-immunosuppression cessation)

• Annual ECHO (pulmonary hypertension surveillance), brain MRI, ophthalmology, renal function

• GAF Healthcare provides structured telemedicine follow-up reports to the patient's local physician, with emergency re-admission protocols clearly documented